536 related articles for article (PubMed ID: 19389331)
1. Akathisia: an updated review focusing on second-generation antipsychotics.
Kane JM; Fleischhacker WW; Hansen L; Perlis R; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Apr; 70(5):627-43. PubMed ID: 19389331
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
[TBL] [Abstract][Full Text] [Related]
3. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Stip E
Expert Opin Drug Saf; 2012 Sep; 11(5):713-32. PubMed ID: 22913713
[TBL] [Abstract][Full Text] [Related]
4. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
Gentile S
J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
6. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
7. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotics for children and young adults: a comparative effectiveness review.
Seida JC; Schouten JR; Boylan K; Newton AS; Mousavi SS; Beaith A; Vandermeer B; Dryden DM; Carrey N
Pediatrics; 2012 Mar; 129(3):e771-84. PubMed ID: 22351885
[TBL] [Abstract][Full Text] [Related]
9. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
10. DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia.
Lawford BR; Barnes M; Swagell CD; Connor JP; Burton SC; Heslop K; Voisey J; Morris CP; Nyst P; Noble EP; Young RM
J Psychopharmacol; 2013 Apr; 27(4):343-8. PubMed ID: 23118020
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis.
Zhang JP; Gallego JA; Robinson DG; Malhotra AK; Kane JM; Correll CU
Int J Neuropsychopharmacol; 2013 Jul; 16(6):1205-18. PubMed ID: 23199972
[TBL] [Abstract][Full Text] [Related]
12. Akathisia and Newer Second-Generation Antipsychotic Drugs: A Review of Current Evidence.
Chow CL; Kadouh NK; Bostwick JR; VandenBerg AM
Pharmacotherapy; 2020 Jun; 40(6):565-574. PubMed ID: 32342999
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.
Cohen D; Bonnot O; Bodeau N; Consoli A; Laurent C
J Clin Psychopharmacol; 2012 Jun; 32(3):309-16. PubMed ID: 22544019
[TBL] [Abstract][Full Text] [Related]
15. Selection of atypical antipsychotics for the management of schizophrenia.
Sprague DA; Loewen PS; Raymond CB
Ann Pharmacother; 2004 Feb; 38(2):313-9. PubMed ID: 14742771
[TBL] [Abstract][Full Text] [Related]
16. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
Zuddas A; Zanni R; Usala T
Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
[TBL] [Abstract][Full Text] [Related]
17. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
18. EPS profiles: the atypical antipsychotics are not all the same.
Weiden PJ
J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.
Edwards SJ; Smith CJ
Clin Ther; 2009 Jun; 31 Pt 1():1345-59. PubMed ID: 19698898
[TBL] [Abstract][Full Text] [Related]
20. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
